Not yet Kvalitetsscore: 42/100

Platelet-Rich Plasma: New Performance Understandings and Therapeutic Considerations in 2020

International Journal of Molecular Sciences · 2020

KeyPRP Platelet-Rich PlasmaRCT Randomised Controlled Trial

A widely-cited PRP mechanism review, not a clinical trial, it explains the biology, not whether PRP actually works for your patient.

sports-medicinerehabilitationtendinopathyosteoarthritislow-back-painpain-science

Studiet

Narrative review (non-systematic), no original patient cohort, synthesizes in vitro, animal, and human PRP literature on formulation and mechanism.

Hvad de fandt

No quantitative clinical outcomes are reported. The review summarizes proposed mechanisms (platelet growth factor release, leukocyte-driven immunomodulation, serotonin/pain effects, angiogenesis) and argues that PRP formulation variables (platelet dose, leukocyte content) explain inconsistent clinical results across studies.

Vurderingen

This is a mechanistic/narrative review, not a controlled study, there is no described systematic search strategy, no risk-of-bias assessment, and no pooled effect estimates, so it cannot itself establish efficacy. Its value is conceptual: explaining why heterogeneous PRP preparations produce conflicting RCT results, not demonstrating that any specific PRP protocol works. The abstract explicitly flags that non-clinical (in vitro/animal) findings often fail to translate to human outcomes, which is an honest and important caveat but also underscores the evidence gap.

Begrænsningen

It doesn't tell you which PRP formulation (platelet count, leukocyte-rich vs. -poor, activation method) actually improves patient-relevant outcomes for a given condition, that requires standardized-formulation RCTs with clinical endpoints, which this review does not provide.

Referencestudie

Sits within the long-running PRP classification debate (e.g., Mishra/DEPA-type classification systems) that arose precisely because unstandardized formulations made trials like those in Achilles and patellar tendinopathy hard to compare or replicate; this paper extends that mechanistic rationale rather than resolving the RCT heterogeneity itself.

Hvad du gør på mandag

No, this doesn't change Monday's practice. It's background reading that should make clinicians more skeptical of generic 'PRP' as a single intervention and more attentive to reported formulation details when appraising any individual PRP trial or product.

Læs den primære kilde ↗

De fem studier, der betyder noget — hver uge, gratis.

Vi læser hele litteraturen om sportsmedicin, genoptræning og præstation og vurderer de studier, der er din tid værd.

Få den gratis ugentlige udgave

Relaterede vurderinger

Læs på dit sprog: English · Français · Deutsch · Español · Italiano · Nederlands · Dansk · Svenska